2677.Hk
The company operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through the provision of healthcare services and pharmaceutical products.
Business. The company operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through the provision of healthcare services and pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through the provision of healthcare services and pharmaceutical products.
The company's capital structure is characterized by a negative total equity of CNY -1,635,993,000 and a high long-term debt of CNY 2,550,268,000, indicating a significant reliance on debt financing. The liquidity position is further constrained by a current ratio of 0.25, suggesting limited short-term liquidity to cover immediate liabilities. The company's market capitalization is CNY 1,472,434,260, with a price-to-earnings ratio of 10.9, which is relatively low compared to industry norms.
Profitability metrics reveal a return on assets (ROA) of 10.11%, which is positive but must be interpreted cautiously given the negative equity position. The return on equity (ROE) is negative at -8.26%, indicating that the company is not generating returns for its shareholders. The operating income of CNY 27,779,000 and net income of CNY 135,064,000 suggest some level of operational efficiency, but the overall financial health is compromised by the high debt levels.
The company's revenue is concentrated in a single segment, as no specific segments are disclosed, and there is no geographic breakdown provided in the available data. This lack of diversification could pose a risk if the primary market experiences a downturn.
The company's growth trajectory is uncertain, as the outlook for the current and next fiscal years is not provided in the available data. However, the operating cash flow of CNY 211,248,000 and free cash flow of CNY 215,454,000 indicate some capacity to fund operations and potentially invest in growth.
The risk assessment highlights a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt underscores the company's financial vulnerability. The dilution potential is low, but the company's high debt levels could necessitate future equity issuances, which would increase dilution risk.
Recent events and filings are not detailed in the available data, but the company's financial statements and risk factors suggest a need for close monitoring of its debt management and liquidity strategies.
- The company has a negative equity position and a high debt-to-equity ratio, indicating significant financial leverage and potential insolvency risk.
- The company's liquidity is constrained, with a current ratio of 0.25, suggesting limited ability to meet short-term obligations.
- The company's profitability is mixed, with a positive ROA but a negative ROE, indicating operational efficiency but poor shareholder returns.
- The company's growth trajectory is uncertain, and there is a lack of segment and geographic diversification, increasing exposure to market-specific risks.
- The company's risk profile includes medium liquidity risk and low dilution risk, with a key flag of negative net cash after subtracting total debt.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- 2677.HK Market data — financials · 2026-05-26